Clinical Trial Update: Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029） [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating anlotinib after chemoradiotherapy in stage III non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Anhui Shi, MD | Conditions: Non-Small Cell Lung Cancer Stage III | Phase 2 | Status: COMPLETED